$71.97
0.46% yesterday
Nasdaq, Aug 11, 10:00 pm CET

Corcept Therapeutics Incorporated. Stock price

$71.97
+0.09 0.13% 1M
+3.86 5.67% 6M
+21.58 42.83% YTD
+37.86 110.99% 1Y
+44.00 157.31% 3Y
+58.46 432.72% 5Y
+66.55 1,227.86% 10Y
+66.68 1,260.49% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.33 0.46%

Key metrics

Basic
Market capitalization
$7.6b
Enterprise Value
$7.2b
Net debt
positive
Cash
$344.7m
Shares outstanding
105.3m
Valuation (TTM | estimate)
P/E
65.4 | 51.2
P/S
10.6 | 8.3
EV/Sales
10.1 | 7.9
EV/FCF
40.2
P/B
11.9
Financial Health
Equity Ratio
80.9%
Return on Equity
20.8%
ROCE
15.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$716.1m | $917.0m
EBITDA
$103.8m | $112.5m
EBIT
$102.0m | $116.6m
Net Income
$133.7m | $147.9m
Free Cash Flow
$180.3m
Growth (TTM | estimate)
Revenue
25.7% | 35.9%
EBITDA
-19.2% | -18.6%
EBIT
-20.3% | -14.9%
Net Income
6.1% | 4.8%
Free Cash Flow
46.2%
Margin (TTM | estimate)
Gross
98.4%
EBITDA
14.5% | 12.3%
EBIT
14.2%
Net
18.7% | 16.1%
Free Cash Flow
25.2%
More
EPS
$1.1
FCF per Share
$1.7
Short interest
14.4%
Employees
500
Rev per Employee
$1.4m
Show more

Is Corcept Therapeutics Incorporated. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Corcept Therapeutics Incorporated. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Corcept Therapeutics Incorporated. forecast:

Buy
90%
Hold
10%

Financial data from Corcept Therapeutics Incorporated.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
716 716
26% 26%
100%
- Direct Costs 12 12
37% 37%
2%
704 704
26% 26%
98%
- Selling and Administrative Expenses 352 352
63% 63%
49%
- Research and Development Expense 251 251
15% 15%
35%
104 104
19% 19%
15%
- Depreciation and Amortization 1.89 1.89
244% 244%
0%
EBIT (Operating Income) EBIT 102 102
20% 20%
14%
Net Profit 134 134
6% 6%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Corcept Therapeutics Incorporated. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corcept Therapeutics Incorporated. Stock News

Positive
Seeking Alpha
4 days ago
Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment issues, but true demand and revenue growth may be accelerating as a large new market is penetrated, pharmacy capacity expands, and new products launch. Physician adoption of Corcept's therapies is...
Neutral
Seeking Alpha
11 days ago
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secretary Joseph K. Belanoff - Co-Founder, President, CEO & Director Roberto W.
Neutral
Business Wire
12 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results “The second qu...
More Corcept Therapeutics Incorporated. News

Company Profile

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.

Head office United States
CEO Joseph Belanoff
Employees 500
Founded 1998
Website www.corcept.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today